News
RHHVF
446.54
NaN%
--
FDA Accepts Roche's Fenebrutinib NDA Under Priority Review For Relapsing And Primary Progressive MS, Backed By Phase III Data Showing 51.1%, 58.5% Relapse Reductions Vs Teriflunomide
Benzinga · 1h ago
Roche Subsidiary TIB MOLBIOL Launches LightMix Newborn TREC/SMN1/HBB Kit To Screen Newborns For SMA, SCID And Sickle Cell Disease Simultaneously
Benzinga · 1h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Adagene (ADAG) and Inventiva (IVA)
TipRanks · 21h ago
Deutsche Bank Sticks to Their Hold Rating for Roche Holding AG (RHHVF)
TipRanks · 22h ago
Weekly Report: what happened at RHHVF last week (0921-0925)?
Weekly Report · 1d ago
Roche: Latest Obesity Data Suggests Pharma Is In Line To Become Global GLP-1 Player
Seeking Alpha · 6d ago
Roche Holding AG (RHHVF) Receives a Buy from RBC Capital
TipRanks · 6d ago
Roche’s Genentech reports ‘positive’ results from Phase 3 Imagination study
TipRanks · 6d ago
Roche Holding AG (RHHVF) Gets a Hold from Berenberg Bank
TipRanks · 6d ago
Roche's Sefaxersen Meets Primary Endpoint In Phase III IMAgINATION Study, Significantly Reduces Proteinuria Versus Placebo At 37 Weeks In IgA Nephropathy Patients
Benzinga · 09/23 06:23
Zealand announces initiation of registrational Phase 3 ZUPREME program
TipRanks · 09/22 15:05
Roche says Phase II obesity study met both primary endpoints
TipRanks · 09/22 09:20
Roche's Enicepatide Meets Both Primary Endpoints In Phase II Trial, Delivering Dose-Dependent Glucose And Weight Reductions In Type 2 Diabetes And Obesity Patients
Benzinga · 09/22 06:15
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA
Seeking Alpha · 09/21 21:14
Roche reports European Commission approves Susvimo for nAMD
TipRanks · 09/21 15:50
Trump Trade: U.S. announces deal with Denmark over Greenland’s security
TipRanks · 09/21 14:16
Weekly Report: what happened at RHHVF last week (0914-0918)?
Weekly Report · 09/21 09:14
U.S. weighs allowing most pharma licensing deals with China, Reuters says
TipRanks · 09/18 14:40
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Seeking Alpha · 09/18 13:22
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents
TipRanks · 09/18 11:30
More
Webull provides a variety of real-time RHHVF stock news. You can receive the latest news about Roche Hldg through multiple platforms. This information may help you make smarter investment decisions.
About RHHVF
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.